Every 10-Q that Quanterix (QTRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QTRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QTRX filings page.
Quanterix Corporation reported stronger top-line results but significantly higher losses for the quarter ended June 30, 2026. Revenue rose 34% to $32.9 million (six-month revenue $69.3 million vs. $54.8 million a year earlier), driven largely by the 2025 acquisition of Akoya Biosciences, which added spatial biology instruments and services. Legacy Quanterix product and service revenue declined amid weaker academic and pharma demand and a constrained capital spending environment.
Profitability was heavily impacted by non-cash charges. The company recorded a $26.9 million goodwill impairment in Q2 and a $19.3 million impairment of in‑process R&D earlier in 2026 tied to a terminated development agreement, leaving goodwill fully written off. Net loss was $48.9 million for Q2 and $66.5 million for the first half, with operating cash outflow of $23.2 million. Quanterix ended June with $44.2 million in cash and $49.4 million in marketable securities, and stockholders’ equity of $237.2 million.
Strategically, management is refocusing on research tools growth and Alzheimer’s diagnostics. The company submitted a 510(k) application for a multi‑analyte blood test for Alzheimer’s disease and is promoting its LucentAD Complete LDT, which has a Medicare reimbursement rate of $897 and new commercial coverage starting July 1, 2026. Integration of Akoya is substantially complete, with approximately $85 million of annualized cost synergies realized, while contingent earnouts related to prior acquisitions remain in place.
Quanterix Corporation reported higher revenue but a mixed bottom line for the quarter ended March 31, 2026. Total revenue rose to $36.4 million from $30.3 million, driven by the 2025 acquisition of Akoya Biosciences, which contributed $8.7 million of product revenue and $3.7 million of service revenue. Legacy Quanterix product revenue fell as U.S. federal research funding cuts and macro-economic pressures reduced consumables demand and Accelerator Laboratory volumes.
Gross profit increased slightly to $15.6 million, but the gross margin declined to 43%, and the operating loss widened to $41.4 million due to a $19.3 million impairment of in‑process R&D tied to a terminated Akoya diagnostic development agreement. That termination also generated $21.6 million of one-time other income. Net loss improved to $17.5 million, or $0.37 per share. Quanterix ended the quarter with $36.2 million in cash and cash equivalents and $63.1 million in marketable securities and continues to target cash flow breakeven in the second half of 2026 while advancing its Alzheimer’s diagnostics strategy, including a 510(k) submission for a multi‑analyte blood test and Medicare pricing of $897 for its LucentAD Complete test.
Quanterix Corporation (QTRX) reported Q3 2025 results with total revenues of $40.2 million, up from $35.8 million a year ago, driven by stronger product revenue of $26.2 million versus $19.7 million. Service and other revenue was $14.0 million, roughly flat year over year. Gross profit was $17.2 million compared with $20.2 million, as costs rose with the expanding business.
The company recorded a net loss of $33.5 million (vs. $8.4 million), reflecting higher selling, general and administrative expenses of $39.1 million, $7.2 million of impairment and restructuring costs, and $5.2 million of Akoya acquisition-related costs. Year-to-date operating cash flow used was $60.8 million. Cash and cash equivalents were $38.3 million and marketable securities $96.5 million at September 30, 2025.
Quanterix closed the Akoya Biosciences acquisition on July 8, 2025, with total consideration of $151.0 million, including $49.2 million in stock, $18.9 million in cash to shareholders, $82.1 million to extinguish debt, and recognized $121.8 million of acquired intangible assets and $23.5 million of goodwill. The quarter included $1.2 million of non-cash revenue from amortizing an acquired off‑market contract liability.